Travere Therapeutics, Inc. (NASDAQ:TVTX) is among the 10 Best Growth Stocks Under $100 to Buy Now. HC Wainwright & Co., a ...

Travere Therapeutics has turned music mogul, bringing together a singer-songwriter and Grammy-winning producer to create an ...

Travere Therapeutics focuses on rare kidney and metabolic diseases, with strong revenue growth from recently approved Filspari and a narrowing loss in Q1 2024. Analysts generally remain bullish ...

Travere Therapeutics is testing a buy point of 21.35, according to IBD MarketSurge. Shares are taking a pause after a smooth rally in a double-bottom base when the stock rose on 11 out of the past ...

The RSUs vest over four years, with 25% of the shares vesting on each anniversary of the grant date, subject to the new employee’s continued service relationship with Travere through the applicable ...

SAN DIEGO, June 11, 2025--Travere Therapeutics today announced that the Company will present three abstracts at the upcoming International Podocyte Conference. SAN DIEGO, June 10, 2025--Travere ...

The latest price target for Travere Therapeutics (NASDAQ:TVTX) was reported by Wedbush on May 16, 2025. The analyst firm set a price target for $30.00 expecting TVTX to rise to within 12 months (a ...

Some Endothelin Receptor Antagonists (ERAs) have caused elevations of aminotransferases, hepatotoxicity, and liver failure. In clinical studies, elevations in aminotransferases (ALT or AST) of at ...

Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that on June 10, 2025, the Compensation Committee of its Board of Directors granted inducement equity grants to 15 new employees ...